From Research at med.fsu.edu Fri Jan 8 14:51:20 2021 From: Research at med.fsu.edu (Med Research) Date: Fri, 8 Jan 2021 19:51:20 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A178217A@FSUCOM128.med.ad.fsu.edu> PhRMA Foundation: Health Outcomes Research The PhRMA Foundation supports the research and early-career endeavors of scientists in drug discovery and development. To that end, the foundation welcomes applications for its Pharmacoeconomics, Real World Data and Health Outcomes Program (Health Outcomes Research). The program supports a broad spectrum of issues related to healthcare delivery, from studies evaluating the effectiveness of a pharmaceutical intervention, to the impact of reimbursement policies on outcomes of care, to the development and use of patient-level real-world data and tools to perform patient-based assessments, to analyses of ways in which results of Health Outcomes Research are disseminated to providers or consumers to encourage behavior change. Grants of up to $100,000 will be awarded to support individuals beginning independent research careers in health outcomes at the faculty level in support of: * Pharmacoeconomics ? Research evaluating the behavior of individuals, organizations, and markets concerning use of pharmaceutical products, services, and programs. * Clinical Outcomes Assessment (COA) ? Research dedicated to the value assigned to duration of life as modified by the impairment of physical, social, and psychological functional states, symptoms, satisfaction, perceptions, and opportunities influenced by disease, injury, treatment, or policy. * Patient-level Real-World Data and Analytic Tools ? The evolving and increasing use and evaluation of technologies, analyses, and patient-level prospective databases (e.g., electronic medical records, health insurance claims data, registries, patient health-networks, patient health status monitoring) to assist in better understanding disease and interventions. Due February 3, 2021. Med-RA deadline to receive draft documents: January 21. Music and Health: Understanding And Developing Music Medicine (R21 / R01 Clinical Trial Optional) R21 R01 These FOAs are intended to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders. R21 Due February 16, 2021; February 16, 2022; and February 16, 2023. Med-RA deadline to receive draft documents for February 2021 due date: February 3. R01 Due February 5, 2021; February 5, 2022; and February 5, 2023. Med-RA deadline to receive draft documents for February 2021 due date: January 25. Alzheimer?s Drug Discovery Foundation: Prevention Beyond the Pipeline The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. The Prevention Pipeline RFP supports: 1. Studies of Cognitive Decline and Risk Reduction: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include epidemiology or clinical trials. For clinical trial proposals, please see below detailed instructions and priorities under ?Expectations and Evaluation?. 2. Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer?s or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper). Methods may include randomized trials or epidemiology. 3. Studies Leveraging the Consortium of Cohorts for Alzheimer?s Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to supplements or medications. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here. Type of therapy: Novel, repurposed and repositioned drugs, as well as natural products and devices will be considered. Therapeutic modalities of interest include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered. Drug mechanisms or modes of action: Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia are considered high priority. These include, but are not limited to: * Epigenetics * Inflammation * Mitochondrial & metabolic function * Neuroprotection * Proteostasis * Synaptic activity and neurotransmitters * Vascular function * Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells) * Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process * Please note: Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered Grants of up to $3,000,000 will be awarded for clinical trials based on stage and scope of research. Letter of intent due February 5, 2021; May 28, 2021; October 1, 2021. Med-RA deadline to receive draft documents for February due date: January 25. Klingenstein-Simons Fellowship Awards in Neuroscience The Klingenstein-Simons Fellowship supports early-career investigators engaged in basic or clinical research that may lead to a better understanding of neurological and psychiatric disorders. Several areas within neuroscience are of particular interest: * Cellular and molecular neuroscience. Studies of the mechanisms of neuronal excitability and development, and of the genetic basis of behavior. * Neural systems. Studies of the integrative function of the nervous system. * Translational research. Studies designed to improve our understanding of the causes, prevention, diagnosis, and treatment of neurological and psychiatric disorders. $225,000 over three years, no IDC. Due February 15, 2021. Med-RA deadline to receive draft documents: February 2. American Psychological Foundation: Walter Katkovsky Research Grants Up to $20,000. APF Walter Katkovsky Research Grants support research on the general topic of psychotherapy. Research proposals should be directed to questions and hypotheses designed to improve our understanding based on theory or methods of how psychotherapy promotes behavioral, emotional, or cognitive changes. While the ultimate goal of the research should be to inform the psychotherapy process, its specific focus may be limited to an underlying assumption, hypothesis, or questions; and the actual design may be ?clinical? or ?experimental? in terms of subjects and procedures. That is, the research design may be a simulation of some aspect of the psychotherapy process (e.g., learning or exposure trials) and subjects may or may not be classified as ?patients?. Due March 1, 2021. Med-RA deadline to receive draft documents: February 16. Enabling Discovery through GEnomics (EDGE) Through the Enabling Discovery through GEnomics (EDGE) program, the National Science Foundation (NSF) and the National Institutes for Health (NIH) support research to advance understanding of comparative and functional genomics. The EDGE program supports the development of innovative tools, technologies, resources, and infrastructure that advance biological research focused on the identification of the causal mechanisms connecting genes and phenotypes. The EDGE program also supports functional genomic research that addresses the mechanistic basis of complex traits in diverse organisms within the context (environmental, developmental, social, and/or genomic) in which they function. These goals are essential to uncovering the rules that underlie genomes-to-phenomes relationships and predict phenotype, an area relevant to Understanding the Rules of Life: Predicting Phenotype, one of the 10 Big Ideas for NSF investment. The goals also support the NHGRI priority to establish the roles and relationships of all genes and regulatory elements in pathways, networks, and phenotypes. The EDGE program will accept proposals to two submission tracks: FUNCTIONAL GENOMIC TOOLS (FGT) TRACK: Proposals submitted to this track should aim to develop and provide proof-of-concept tests of functional genomic tools and infrastructure to enable direct tests of hypotheses about gene function in diverse species for which such tools and infrastructure are presently unavailable. Investigators may use taxonomic, question-based, and/or technology-based strategies to develop tools and approaches that will be employed by larger communities of researchers. Projects may include instrumentation development followed by proof-of-concept testing in the context of developing functional genomic tools to enable direct tests of gene function. COMPLEX MULTIGENIC TRAITS (CMT) TRACK: Proposals submitted to this track should include hypothesis-driven research that advances understanding of the relationship between genomes and complex multi-genic traits, toward the goal of predicting phenotypes across diverse contexts, including environmental, developmental, social, and/or genomic contexts. Successful proposals may include the development of theory and/or analytical approaches to achieve the scientific goal. The EDGE program recognizes that many of the traits of interest to biologists are quantitative in nature and are controlled by many genes of small effect and that understanding complex traits requires systems-level analysis of the underlying gene regulatory networks that goes beyond linking individual genes with said traits. Submissions to the COMPLEX MULTIGENIC TRAITS TRACK should emphasize the contribution of genome-wide factors that impact expression of a phenotype. NSF-BSF Proposals: The EDGE program will accept proposals for the joint NSF/US-Israel Binational Science Foundation (BSF) collaborative research opportunity. More information can be found in the Dear Colleague Letter at: https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20094__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKH5u_T50$ and subsequent replacements. Due March 16, 2021 and February 17, 2022. Med-RA deadline to receive draft documents for March due date: March 3. NSF Dear Colleague Letter: IMAGiNE FG: Functional Genomics The Division of Integrative Organismal Systems (IOS) has developed a thematic research focus entitled Integrating Mechanisms of Adaptation with Genes in Networks and across Environments (IMAGiNE). A Dear Colleague Letter (DCL), NSF 20-044 IMAGiNE: 2020: Organisms in a Dynamic Environment ? was issued that is still current and actively encouraging submission of proposals addressing how organism-environment interactions determine the emergence of complex traits. This DCL (IMAGiNE FG: Functional Genomics) complements and extends the IMAGiNE theme. Here, the focus is to encourage research on the organismal mechanisms, analytical frameworks, and biological theories that advance our understanding of the connection between an organism?s genome and its phenotype, i.e., functional genomics. In an effort to develop strategies to move the field of functional genomics forward the National Academies of Sciences, Engineering, and Medicine (NASEM) in Washington, DC recently held a workshop entitled ?Next Steps for Functional Genomics.? [1] The goals of the workshop were to determine the current state of research in functional genomics and to identify the factors limiting advancements in this field. This IMAGiNE FG: Functional Genomics DCL acts on the proceedings of the NASEM workshop by encouraging the submission of proposals that include the dual criteria of research that (1) is relevant to any of the programs in the Integrative Organismal Systems Core Programs solicitation NSF 21-506 (, the Plant Biotic Interactions (PBI) solicitation NSF 20-576, or the Plant Genome Research Program (PGRP) solicitation NSF 21-507 and (2) addresses obstacles to moving the field of functional genomics forward as identified in the NASEM workshop report. Proposals accepted any time. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor. Mood Disorders in People Living with HIV: Mechanisms and Pathways (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these Funding Opportunity Announcements (FOAs) is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living with HIV. Due March 10, 2021. Med-RA deadline to receive draft documents: February 25. Congressionally Directed Medical Research Programs Breast Cancer Research Program Breakthrough Award Levels 1 and 2 Pre-application (letter of intent): March 11, 2021. Application: March 25, 2021. Breakthrough Award Level 3 Pre-application (preproposal): March 12, 2021. Invited full application: June 23, 2021. Breakthrough Award Level 4 Pre-application (preproposal): March 12, 2021. Invited full application: June 23, 2021. Era of Hope Scholar Award Pre-application (letter of intent): March 11, 2021. Application: March 25, 2021. Confidential letters of recommendation: June 25, 2021. Pre-application (preproposal): March 12, 2021. Invited full application: June 23, 2021. Med-RA deadline to receive draft documents for the above pre-application due dates: March 1. Improving Health Disparities in Alcohol Health Services (R01 Clinical Trial Optional) This Funding Opportunity Announcement solicits applications on health disparities and health services-related research focusing on: 1) access to treatment, 2) making treatment more appealing, 3) costs, and 4) dissemination and implementation. All applications are expected to emphasize health disparities in addition to the other four areas of focus mentioned above. Due March 15, 2021. Med-RA deadline to receive draft documents: March 2. Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 ? Clinical Trial Optional) This funding opportunity is intended to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease among individuals with Type 1 Diabetes Mellitus (T1DM) and advances the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. Due March 15, 2021 and October 15, 2021. Med-RA deadline to receive draft documents for March due date: March 2. New Approaches to Identify Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed) The goal of this Funding Opportunity Announcement is to support research on novel approaches and/or innovative expansion of existing approaches to identify the presence of neurogenesis and study its dynamics in brain aging and AD/ADRD. Due June 17, 2021. Med-RA deadline to receive draft documents: June 7. Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required) The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES. Due June 22, 2021; June 22, 2022; and June 22, 2023. Med-RA deadline to receive draft documents for June 2021 due date: June 9. NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval. Due July 26, 2021; July 25, 2022; and July 25, 2023. Med-RA deadline to receive draft documents for July 2021 due date: July 13. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Jan 15 16:16:22 2021 From: Research at med.fsu.edu (Med Research) Date: Fri, 15 Jan 2021 21:16:22 +0000 Subject: Weekly Funding Opportunities In-Reply-To: <317A4030-EF5D-4D5E-B555-D6CB376BCD77@med.fsu.edu> References: <317A4030-EF5D-4D5E-B555-D6CB376BCD77@med.fsu.edu> Message-ID: <678887EBDC79FB438BFD062B064C59A401A1785098@FSUCOM128.med.ad.fsu.edu> National Institute of Standards and Technology: Precision Measurement Grant Program (PMGP) ? see attached notice of funding opportunity The PMGP is seeking applications to support significant research in the field of fundamental measurement or the determination of fundamental constants. See Bioscience Topic Area for examples of projects/programs of interest. Notice of Funding Opportunity attached. Abbreviated applications (~5 double spaced pages) due February 17, 2021. Med-RA deadline to receive draft documents: February 4. Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to encourage theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this FOA include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings. Due February 16, 2021; June 16, 2021; October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; and October 16, 2023. Med-RA deadline to receive draft documents for February 2021 due date: February 3. Pediatric Cancer Research Foundation: Research Grants The Pediatric Cancer Research Foundation awards three types of grants: * Emerging Investigator Fellowship Grants: $50,000 / year; can be renewed annually * Translational Research Grants: multi-year; $100,000 / year * Basic Science Grants: multi-year; $250,000 / year Letter of intent due March 1, 2021. Med-RA deadline to receive draft documents: February 16. Foundation for Prader-Willi Research The Foundation for Prader-Willi Research addresses the many issues related to Prader-Willi Syndrome, including childhood obesity, developmental delay, psychiatric disorders, and autism spectrum disorders. FPWR is particularly interested in supporting projects that will lead to new treatments to alleviate the symptoms associated with PWS. Funding priorities include: * Genotype to phenotype: understanding PWS genetics / how loss of PWS-critical region genes leads to the phenotype * Neurobiology of hunger / feeding behavior in PWS * Neurobiology of cognitive deficits, maladaptive behavior and mental illness in PWS * Clinical care research: evaluation of existing drugs and interventions to improve health and quality of life in PWS * Therapeutics development for PWS- Genetic therapies; novel pharmaceuticals; drug repurposing for PWS One-year projects; $100,000; 8% IDC. Letter of intent due March 5, 2021. Med-RA deadline to receive draft documents: February 22. Cellular Senescence Network: Technology Development and Application (UG3 / UH3 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to solicit novel analytics and technologies to identify senescent cells in human tissues This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in mammalian tissues. The subsequent UH3 phase is to support initial validation in human tissues, optimization and scale-up, and generation of production level data. Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds. Due March 8, 2021. Med-RA deadline to receive draft documents: February 23. Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Aging and Alzheimer?s Disease (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the regulation of brain regional and cell-type-specific proteome dynamics in Alzheimer?s disease (AD). Specifically, this FOA encourages collaborative approaches to design and implement novel, single-cell-based proteomic platforms to comprehensively characterize the dynamics of neuronal proteomes during the course of aging and AD. Due March 18, 2021. Med-RA deadline to receive draft documents: March 8. HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional) In April 2018, the National Institutes of Health (NIH) launched the HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. In response to this initiative, the National Institute of Mental Health (NIMH), in partnership with other NIH Institutes, Centers, and Offices, invites research that will optimize multi-component service delivery interventions for people with opioid use disorder (OUD) and co-occurring conditions, to include mental disorders and/or suicide risk. The purpose of the initiative is to support studies that will (1) test the overall effectiveness of multi-component interventions for OUD and co-occurring conditions and (2) examine the relative contribution of constituent components to overall effectiveness. This research will streamline service packages so they only include components that drive clinical improvements for complex conditions. Due March 18, 2021. Med-RA deadline to receive draft documents: March 8. HEAL Initiative: HEALthy Brain and Child Development Study (U01 / Collaborative U01 ? Clinical Trial Not Allowed) U01 Collaborative U01 The purpose of these Funding Opportunity Announcements (FOAs) is to seek applications for unlinked Research Project Sites for the HEALthy Brain and Child Development (HBCD) Study using the cooperative agreement award mechanism. It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. These FOAs seek applications to create a consortium of research sites in service of the nationwide, multi-site, multi-modal, longitudinal cohort HBCD Study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on outcomes. Research sites will enroll pregnant women and collect data from them and their children using methodologies that include neuroimaging, neurophysiology, behavioral and cognitive assessments and collection of biospecimens. Due March 31, 2021. Med-RA deadline to receive draft documents: March 18. Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional) This Funding Opportunity Announcement seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research. Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for May 5 standard date: April 22. Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence of human immunodeficiency virus (HIV). Standard dates apply. Expires January 8, 2022. Med-RA deadline to receive draft documents for May 7 standard date: April 26. NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Due May 12, 2021; September 14, 2021; January 12, 2022; May 13, 2022; September 14, 2022; January 13, 2023; and May 12, 2023. Med-RA deadline to receive draft documents for May 2021 due date: April 29. NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Due May 14, 2021; September 13, 2021; January 14, 2022; May 13, 2022; September 13, 2022; January 13, 2023; May 13, 2023; September 14, 2023; and January 13, 2024. Med-RA deadline to receive draft documents for May 2021 due date: May 3. Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens or environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population. Due June 4, 2021. Med-RA deadline to receive draft documents: May 24. EMDR Foundation Research Grants Grant awards of up to $25,000 are available for post-doctoral students, university faculty, or clinicians conducting research on Eye Movement Desensitization and Reprocessing (EMDR). Current research priorities include: 1st Priority ? Advancing Evidence Based Practice: Increase the availability of quality EMDR research in areas where we already have a foot-hold in the literature but where more evidence is needed. Specifically, those areas are in the use of EMDR therapy to treat: * Anxiety * Depression * Military PTSD * Phantom Limb Pain * To enhance recovery from the impact of cardiac events and the diagnosis and treatment of cancer 2nd Priority ? Addressing the Global Burden of Trauma: Investigate the use of EMDR in natural or man-made disaster responses, by determining the effectiveness of the following protocols: early intervention protocols, the child or adult group protocols, or the use of EMDR standard protocols in disaster response. 3rd Priority ? Building Clinical Evidence: There are a number of areas where EMDR therapy is being used, clinical observations are positive, and there are some research indicators of success. However, more research is needed to build a body of literature in these populations or diagnostic categories, including but not limited to: * Addictions * Eating disorders * Dissociative disorders * Additional medical/somatic conditions * Suicide prevention and/or to address the impact of suicide These priorities apply to research across the lifespan. Due July 1, 2021. Med-RA deadline to receive draft documents: June 21. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: 2021-NIST-PMGP-01 NOFO.pdf Type: application/pdf Size: 333011 bytes Desc: 2021-NIST-PMGP-01 NOFO.pdf URL: From Research at med.fsu.edu Fri Jan 29 15:04:08 2021 From: Research at med.fsu.edu (med-Research) Date: Fri, 29 Jan 2021 20:04:08 +0000 Subject: Weekly Funding Opportunities Message-ID: LUNGevity: Lung Cancer Research Awards Career Development Award LUNGevity?s Career Development Award Program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Research that will be funded in 2021 is expected to have a direct impact on the early detection of lung cancer and/or individualized lung cancer treatment, including through targeted therapy and immunotherapy. Early Detection Award LUNGevity?s Early Detection Award Program supports the development of strategies for the early detection and/or diagnosis of lung cancer. Research that will be funded in 2021 is expected to have a direct impact on the early detection and/or diagnosis of lung cancer or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or diagnosis of lung cancer. Letter of intent due February 24, 2021. Med-RA deadline to receive draft documents: February 8. Sontag Foundation: Distinguished (Early Career) Scientist Award in Brain Cancer Research The Distinguished Scientist Award seeks to provide career and research support to early career scientists who demonstrate outstanding promise for making scientific and medical breakthroughs in the field of brain cancer research. Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer. Applicants are carefully considered and selected by The Sontag Foundation and its independent Scientific Advisory Board based on the scientific merit of the proposed project, career trajectory, peer and mentor references and an onsite research facility visit. In determining the overall scientific merit of an application, the Scientific Advisory Board scores applications based on the NIH review criteria of: significance, investigator, innovation, approach, and environment. The award provides $600,000 in funding over a four-year period. Over that time, recipients also receive additional support from the Foundation through its vast network of scientists in the field primarily through the Foundation?s annual Scientific Retreat. Due March 17, 2021. Med-RA deadline to receive draft documents: March 4. The Doctors Company Foundation: Patient Safety (Education or Research) Grants The purpose of the Doctors Company Foundation is to support patient-safety education for healthcare. Through the program, grants will be awarded to projects/activities aimed at developing knowledge, techniques, and tools whose application reduces or eliminates risk of adverse events that cause harm to patients while under care. Letter of intent due March 22, 2021. Med-RA deadline to receive draft documents: March 9. Infectious Etiology of Alzheimer?s Disease (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) will support applications aimed at: (1) determining whether microbial pathogens represent a causal component of Alzheimer?s disease (AD), (2) establishing mechanisms by which microbial pathogens impact neurodegenerative processes in AD, and (3) informing aspects of future translational studies in AD, including the discovery of candidate therapeutics aimed at regulating pathogen-associated networks and molecules in AD. Due March 31, 2021. Med-RA deadline to receive draft documents: March 18. BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) This FOA seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation (also referred to as stimulation, perturbation, or manipulation). A wide range of modalities are appropriate including acoustic, chemical, electrical, magnetic, optical and chemical, as well as the use of genetic tools. Invasive or non-invasive approaches are sought that will enable large-scale recording and/or precise manipulation of neural activity, and that would ultimately be compatible with experiments in humans or behaving animals. Due May 3, 2021; October 29, 2021; May 2, 2022; October 28, 2022; May 1, 2023; and October 27, 2023. Med-RA deadline to receive draft documents for May 2021 due date: April 20. Institutional Training Programs to Advance Translational Research on Alzheimer?s Disease (AD) and AD-Related Dementias (T32) This Funding Opportunity Announcement (FOA) seeks to enable the development of a diverse, translational research workforce capable of participating and/or leading cross-disciplinary team science programs focused on advancing therapy development for Alzheimer?s disease (AD) and AD-related dementias (ADRD). This FOA will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology, translational and clinical research, data science and behavioral research). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD and AD-related dementias. Due May 25, 2021; September 27, 2021; May 25, 2022; September 26, 2022; May 25, 2023; and September 25, 2023. Med-RA deadline to receive draft documents for May 2021 due date: NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 / R61 / R33 Clinical Trial Required) R33 The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. R61 / R33 The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training. Due June 4, 2021; October 2, 2021; June 4, 2022; October 2, 2022; June 4, 2023; October 2, 2023. Med-RA deadline to receive draft documents for June 2021 due date: To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: